Wenbin Jiang - Feb 7, 2022 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role
President and CEO, Director
Signature
/s/ Valerie Barnett, Attorney-in-Fact for Wenbin Jiang
Stock symbol
CTKB
Transactions as of
Feb 7, 2022
Transactions value $
-$288,000
Form type
4
Date filed
2/9/2022, 04:52 PM
Previous filing
Jul 22, 2021
Next filing
Mar 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTKB Common Stock Gift $0 -5K -0.06% $0.00 7.84M Dec 4, 2021 Direct
transaction CTKB Common Stock Sale -$288K -20K -0.25% $14.40 7.89M Feb 7, 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Includes 66,665 shares received as a liquidation distribution from WYTJ LLC. In prior reports, the Reporting Person reported beneficial ownership of 2,666,600 shares of the Issuer's common stock held by WYTJ LLC.